▷ Qiagen Dividends 【Calendar 2025】

Upcoming Qiagen dividend

Change(%)

0.00%

No change

Next payment N/A

Next payment date N/A

Last payment N/A

Last payment date N/A

00 D 00 H 00 M 00 S

Ex-Dividend: N/A

Not available

When are the upcoming Qiagen dividends in 2025?

▶

Qiagen has not insinuated a dividend policy for 2025.

Dividend policy of Qiagen

▶

Qiagen NV, listed on major stock exchanges in Germany, Austria, the United States and the United Kingdom, using the symbol QIA as the basis for its stock name, announced its first dividend payment in January 2017, but so far, the company has not paid this interest to its shareholders.

Payout Ratio Qiagen Dividends

In the last fiscal period, Qiagen paid no dividends, resulting in a dividend payout ratio of 0%.

Qiagen has not distributed dividends in the last fiscal period, therefore, the payout ratio is 0%.

Dividend payout ratio Payout Ratio

Dividend calendar of Qiagen

There is no Dividend Calendar of Qiagen defined for 2025.

Historical annual dividend yields of Qiagen

Over the past 5 years, Qiagen has not consistently distributed dividends.

Increasing Dividends Dividend yield

Dividend yield history in Qiagen

Over the past 5 years, Qiagen has not consistently distributed dividends.

Dividend stability

Dividend history of Qiagen

In this table you can see the complete history:

Year	Ex-Dividend	Amount	Total
2017	01/25/2017	1.08 €	1.08 €

Information about Qiagen

Full name Qiagen N.V.

Ticker QIA

Sector Health Care

Industry Diagnostics & Research

Market Capitalization 7.92B €

ISIN NL0012169213

Number of Employees 6,000

Description of the company

Qiagen NV. is a company dedicated to the healthcare industry, specialized in providing technology for molecular diagnostics, is present in more than 35 countries, with headquarters in Hilden, Germany.

It was founded in 1984 by a group of scientists belonging to the Heinrich Heine University of Düsseldorf, launching its first product in 1986, a plasmid purification kit, years later they began a series of important acquisitions that expanded internationally and supported the diversification of its activities, such as Molecular Staging, Inc, Digene in 2004, reaching Shanghai, boosting its diagnostic programs.

They subsequently acquired DxS Ltd, SABiosciences Corp, ESE GmbH, Ipsogen SA, Cellestis Limited, Ingenuity Systems, CLC bio, Exiqon, OmicSoft Corporation, NeuMoDx Inc, Verogen, among others, managing to launch a verified diagnostic test for the detection of H1N1 virus, giving them access to test devices for molecular diagnostics, projecting the QIAsymphony AS and QIAsymphony RGQ platforms, and obtaining QuantiFERON technology for the detection and prevention of diseases, in addition to bioinformatics analysis software.

In 2020, it worked closely with public health authorities and governments to ensure the availability of Covid 19 diagnostic tests, creating low-yield and high-yield kits and tests.

Among its products are molecular samples (tissue, fluids, etc.) with which they can stabilize, extract and purify molecules such as DNA, RNA or proteins, amplified to make them visible for interpretation, being applied in the academic research market, molecular diagnostics, oncology, modulation of the immune response and tests for the detection of infectious diseases.